Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Zhengye Biotechnology Holding Limited before investing.

In this article, we go over a few key elements for understanding Zhengye Biotechnology Holding Limited’s stock price such as:

• Zhengye Biotechnology Holding Limited’s current stock price and volume
• Why Zhengye Biotechnology Holding Limited’s stock price changed recently
• Upgrades and downgrades for ZYBT from analysts
• ZYBT’s stock price momentum as measured by its relative strength

About Zhengye Biotechnology Holding Limited (ZYBT)

Before we jump into Zhengye Biotechnology Holding Limited’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People’s Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine. It also develops vaccines for household animals, including rabies vaccine and Strain Flury LEP for dogs. In addition, the company exports its products to Vietnam, Pakistan, and Egypt. It serves direct-end customers, including livestock farmers and local governments; and domestic distributors and exporting distributors. The company was incorporated in 2004 and is based in Jilin, China. Zhengye Biotechnology Holding Limited operates as a subsidiary of Securingium Holding Limited.

Want to learn more about Zhengye Biotechnology Holding Limited’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Zhengye Biotechnology Holding Limited.

What Caused Zhengye Biotechnology Holding Limited Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 29, 2026, there were analysts who downgraded Zhengye Biotechnology Holding Limited’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Zhengye Biotechnology Holding Limited’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Zhengye Biotechnology Holding Limited’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Zhengye Biotechnology Holding Limited’s current valuation based on AAII’s Value Grade is a A, which means it is considered to be Deep Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Zhengye Biotechnology Holding Limited (ZYBT) by visiting AAII Stock Evaluator.

Relative Price Strength of Zhengye Biotechnology Holding Limited

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 29, 2026, Zhengye Biotechnology Holding Limited has a weighted four-quarter relative price strength of -28.50%, which translates to a Momentum Score of 6 and is considered to be Very Weak.

Want to learn more about how Zhengye Biotechnology Holding Limited is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Zhengye Biotechnology Holding Limited Stock Price: Bottom Line

As of June 1, 2026, Zhengye Biotechnology Holding Limited’s stock price is $0.849, which is down 0.16% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Zhengye Biotechnology Holding Limited stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.